Iindaba
-
Ibhulethini yoMmiselo omtsha
1. Imithetho emitsha yokuBhaliswa kwe-FDA kwi-US Cosmetics Cosmetics Ngaphandle koBhaliso lwe-FDA iyakuvinjelwa ekuthengisweni.NgokoMthetho we-Modernization of Cosmetics Regulation Act ka-2022, esayinwe nguMongameli uBiden ngoDisemba 29, 2022, zonke izimonyo ezithunyelwa eUnited States kufuneka zibe yi-FDA-registere...Funda ngokugqithisileyo -
2023 I API 88 yaseTSHAYINA
Ulwazi malunga ne-JYMed ngo-2023 API CHINA 【kwisiza】 Ngaphantsi kobunkokeli be-Vice General Manager Zhi Qin, i-Shenzhen JYMed Technology Co.,Ltd. (emva koku kubhekiselwa kuyo njenge-JYMed) ithathe inxaxheba kulo mboniso mkhulu. I-JYMed ibonise iimveliso eziluncedo iSemaglutide, iLiraglutide, iTirzepatide, iO...Funda ngokugqithisileyo -
Wamkelekile ukudibana nathi kumboniso we-API eQindao China JYMed stock: N4K32
Funda ngokugqithisileyo -
I-JYMed idibene nawe ePCHi
Emva kweminyaka emibini yokulindela, i-2023 China International Cosmetics Personal and Home Care Raw Materials Exhibition (PCHi) yayibanjelwe kwi-Guangzhou Canton Fair Complex ngoFebruwari 15-17, 2023. I-PCHi ngumboniso wezorhwebo wamazwe ngamazwe okhonza izimonyo zehlabathi, ngokwe...Funda ngokugqithisileyo -
I-Semeglutide API ye-Shenzhen JYMed yamkelwe liqela lokuqala le-NMPA yasekhaya kwaye ibhaliswe kwi-US FDA (i-DMF No. 036009) enesimo "A".
NgoMeyi ka-2022, i-Shenzhen JYMed Technology Co., Ltd. (emva koku kubhekiselwa kuyo njenge-peptide ye-JYMed) ingenise isicelo sokubhaliswa kwe-semaglutide API kwi-US Food and Drug Administration (FDA) (inombolo yobhaliso ye-DMF: 036009), Idlulise ukuhlaziywa kokuthembeka, kunye nesimo sangoku ...Funda ngokugqithisileyo
